Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer.

Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for #BreastCancer, by Thomas et al. https://t.co/i7LeolKhCc @MDAndersonNews https://t.co/AyFQQNMa7i

From the January Issue: Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for #BreastCancer, by Thomas et al. https://t.co/caQI7kh6N1 @MDAndersonNews https://t.co/873TpMjPs2

From the January Issue: Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for #BreastCancer, by Thomas et al. https://t.co/gSs0lvoiqU @MDAndersonNews https://t.co/k5ge00dJNy

From the January Issue: Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for #BreastCancer, by Thomas et al. https://t.co/d75MioYEVU @MDAndersonNews https://t.co/9tdGSUIIGt